CELC Celcuity96.93-14.12 (-12.7%)
After Hours Decliner
CELC Celcuity111.05+7.26+7.0%
After Hours:109.29-1.76 (-1.6%)
Celcuity Announces FDA Approval of REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Globe NewswireTue, 14-Jul 4:53 PM
CELC Celcuity102.79-1.00 (-1.0%)
CELC Celcuity88.07-0.88 (-1.0%)
CELC Celcuity88.78-2.64 (-2.9%)
CELC Celcuity93.36-29.60 (-24.1%)